Home>Publications>Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment
Robbins PB, Krieger T, Pearson I, Bell J, Doherty J. Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment. Poster presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium; March 1, 2019. San Francisco, CA.
The power of knowledge. The value of understanding.
Steeped in a tradition of rigor and process, we maintain a legacy of setting the scientific standards within our industry. We employ the right approaches and proven research practices to analyze evidence and draw meaningful insights. Our uncompromisingly ethical and objective researchers ensure that results will hold up to scrutiny and reveal the benefits, risks, value and potential of your products. Learn more.